Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2003, the company has made significant strides in developing innovative therapies for patients with unmet medical needs, particularly in the fields of central nervous system disorders and sleep disorders. Vanda's core products, including the FDA-approved medications Fanapt and Hetlioz, are distinguished by their unique mechanisms of action and targeted therapeutic approaches. The company has established a strong market position, recognised for its commitment to advancing treatment options and improving patient outcomes. With a focus on research and development, Vanda continues to explore new avenues for growth and innovation in the pharmaceutical landscape.
DitchCarbon Score
How does Vanda Pharmaceuticals Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Vanda Pharmaceuticals Inc.'s score of 25 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Vanda Pharmaceuticals Inc.'s reported carbon emissions
Vanda Pharmaceuticals Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges from the company. As a result, Vanda Pharmaceuticals has not established any significant climate commitments or initiatives aimed at reducing its carbon footprint. The lack of emissions data and reduction strategies suggests that the company may still be in the early stages of developing a comprehensive climate action plan. In the broader context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and carbon reduction, often setting science-based targets to align with global climate goals. However, without specific commitments or data from Vanda Pharmaceuticals, it remains unclear how the company plans to address its environmental impact.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Vanda Pharmaceuticals Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
